OraVerse - The New Anesthesia Reversal

Your child's comfort is an important priority in our practice. So if your child dislikes the lingering numbness of local anesthesia or tends to chew their lip or cheek while being numb an innovative solution is here. Our office is now offering a new product called OraVerse®.

OraVerse is the first and only product of its kind to rapidly reverse numbness following your dental procedure so you can feel, speak, smile and drink normally about twice as fast. OraVerse can benefit adults and children six years of age or older and weighing 33 lbs or more.

I was recently asked by Novalar Pharmaceuticals to participate on the advisory board for the development of this product. It has always been my concern that a child who has had local anesthesia runs the risk of biting his or her cheeks, lip or tongue. I have seen many of these cases in my practice post operatively. We have started using this product and have seen the anesthesia time reduced by half. OraVerse is administered by injection, but is not felt by the patient since they are already numb. I am recommending this for patients who have had simple procedures done such as Restorative Fillings, but not procedures such as extractions.

If you have concerns about your child and the lingering numbness from local anesthesia, let's discuss whether OraVerse is the right choice for them during their next dental visit.

For more information, you can visit us at www.larrycaldwelldds.com or www.OraVerse.com

Important Safety Information

Following parenteral use of phentolamine at doses between 5 to 15 times higher than the recommended dose of OraVerse (phentolamine mesylate), myocardial infarction, and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia, bradycardia, and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease; as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents.